AZ’s Lynparza Falls Short in Phase 3

AstraZeneca’s gastric cancer treatment Lynparza flopped in a Phase 3 study, failing to meet its primary endpoint of improving overall survival.

The company said that patients taking the drug in combination with chemotherapy showed an improved survival trend versus those just taking chemotherapy, but the trend was not statistically significant.

AstraZeneca still is reviewing all the data and will present them at a later date.